Cadrenal Therapeutics Aligns Portfolio, Seeks Partners for Late-Stage Assets
Cadrenal Therapeutics announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. The company has initiated a structured process to secure strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets, including CAD-1005, frunexian, and tecarfarin. This strategy aims to maximize asset value and accelerate commercialization, supported by recent positive Phase 2 data for CAD-1005 showing a significant reduction in thrombotic events. Additionally, Cadrenal is advancing its preclinical oral 12-LOX inhibitor, CAD-2000, and expanding tecarfarin's clinical protocols for rare pediatric diseases like Kawasaki Disease.
Key Highlights
- Aligned clinical portfolio into a Cardiac Acute Critical Care Franchise.
- Initiated structured process to secure out-licensing, monetization, or co-development partnerships for late-stage assets.
- Phase 2 CAD-1005 data demonstrated a greater than 25% absolute reduction in thrombotic events.
- Portfolio structured into three pillars: Pre-Operative Safety, Orphan Regulatory Acceleration, and Post-Operative Shield.
- Expanding tecarfarin's clinical protocols to rare pediatric diseases for potential Priority Review Voucher.
- Advancing preclinical oral 12-LOX inhibitor, CAD-2000, for chronic cardiorenal indications.
Price Impact
More from CVKD